Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

October UNC Health System Pharmacy Resident CE Series (Live Webinars)


Due to concerns about the novel coronavirus, and consistent with ongoing efforts to reduce spread of the virus, attendance for these CE sessions will be WEBINAR ONLY.  Please see instructions below for registration.
 
PLEASE FOLLOW THE STEP-BY-STEP INSTRUCTIONS BELOW – DO NOT SKIP STEPS!
 
STEP 1:  SIGN INTO YOUR ACCOUNT AND REGISTER FOR EACH SESSION YOU WOULD LIKE TO ATTEND
** If you do not register for the CE at this link, you will not be able to access the evaluations to earn credit
** EVERYONE must register BEFORE the session date. NO NEW REGISTRATIONS WILL BE ADDED AFTER THE PROGRAM DATE
** You will receive an email confirming your registration at the email address provided – if you do not receive a confirmation email, try to register again
**New sessions may be added throughout the month, so do not assume you are automatically registered for all sessions.
 
STEP 2:  AFTER SUCCESSFULLY REGISTERING ON THIS SITE - AT THE TIME OF THE PROGRAM, EXPAND THE MODULE AT THE BOTTOM OF THIS PAGE AND CLICK THE WEBEX LINK.
The Link will not be emailed to you. It can only be found on this page.
** submit your contact information
 
STEP 3:  Collect the presenter code for each of the CEs that you attend
** EVERYONE will need the presenter codes to access evaluations and earn CE credit
 
STEP 4:  You will receive an automated email to log in and complete evaluations
** Evaluations must be completed within 60 days of the CE session
** You will need the presenter codes to access each evaluation
** Evaluations MUST be completed within 60 days of the program date to earn CE credit!

Date: Oct 1, 2022 01:00 AM - Oct 31, 2022 11:55 PM

CE Hours

7.00

CE Units

0.700

Registration closes on Oct 31, 2022 11:55 PM

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

Accreditation(s)

Participants have 60 days from the start of their program to claim CE credit and verify it has been upload to CPE Monitor. If your program requires the completion of a post test/eval/survey those items MUST be done before that 60 day window closes to receive credit for that program. Statements of credit can be viewed and printed from CPE Monitor. Statements of credit will no longer be printed and mailed to the participant. **No partial individual session credit will be given**
 
PAYMENT NOTE: During the registration process, if a fee is required, please enter the zip code associated with your credit card's BILLING ADDRESS. For security purposes payments are processed through a separate system, so when prompted, please click “ok” to be taken to that site and complete your registration. Upon successful registration of this program you will receive an email confirmation/receipt and will be returned to this program page. When you are retuned to this page you will see a note at the top of the page reading “You are registered for this program.”
If you are not automatically returned to this page or see only a blank white screen your transaction was not successful, and you will need to try again.

 

If paying by check please mail to the address below:

UNC Eshelman School of Pharmacy
Attn: Continuing Education
301 Pharmacy Lane, CB# 7574 Beard Hall
Chapel Hill, NC 27599
 
 
Accreditation Council for Pharmacy Education
The University of North Carolina Eshelman School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To receive CE credit, participants must complete the CE attendance form and the online evaluation of the program (instructions to be emailed). Statements of credit can be viewed and printed in CPE Monitor approximately 2 to 3 weeks after the program and you have completed any needed requirements. **No partial credit will be available**

Co-Sponsor(s)

UNC Health System

Support/Credits

 
 
 
Cancelations: Cancelations must be received in writing/email to the Office of Continuing Education at least 48 hours prior to start date to receive a full refund. No refunds will be given within 48 hours of the start date.
 
 
IMPORTANT: UNC HEALTH SYSTEM EMPLOYEES AND UNC ESHELMAN SCHOOL OF PHARMACY STUDENTS ONLY
 
UNC Health System Employees and ESOP Students are able to attend this Resident Series at no charge to them. If you are a Health System Employee or Student please follow the steps below. This only applies to this series. Other UNC ESOP CE programs are available to register at the fee listed on that page.
  1. UNC Health System Employees and UNC ESOP Students should register using your UNC email address. UNC Employees - please select your employment location during the registration process. UNC Students - please respond "Yes" to the "Are you a UNC Student" question.
  2. Select the “Check” payment method on the registration page. Your employment will be verified prior to credit being uploaded

 

 

 

   

This presentation will highlight the nuances of drug dosing in patients who have a history of bariatric surgery. A brief review of the physiological changes associated with the most common bariatric procedures and their general effects on pharmacokinetics. The remainder of the presentation will review the available literature surrounding bariatric surgery medication and disease state management. There will be a specific focus on common disease states like hypertension and diabetes and medications such as anticoagulants and antibiotics.
 
 
Meeting ID: 941 9379 5014
Passcode: 464340

Objectives

  • Describe the pharmacokinetic impacts and general medication adjustments necessary following bariatric procedures
  • Explain the pathophysiology and management of dumping syndrome
  • Discuss the effects bariatric surgery has on nutritional and disease state management
  • Outline alternatives to medications impacted by bariatric surgery

Speaker(s)/Author(s)

Chris Bollinger
PharmD, MBA

Activity Number

0046-9999-22-194-L01-P
Date: 10/04/22
Time: 01:00 PM - 02:00 PM

CE Hours

1.00

Fee

$10.00

Location

Online
   

 

   

This presentation aims to highlight new literature evaluating nephrotoxicity associated with vancomycin and piperacillin-tazobactam combination therapy. Vancomycin and piperacillin-tazobactam is a combination that tends to be avoided due to its effect on renal function; in this presentation, we will discuss various acute kidney injury classification systems as well as the combination's effect on different markers of renal function.

Objectives

  • Describe proposed mechanisms and risk factors for vancomycin and piperacillin-tazobactam (VN+PT) nephrotoxicity
  • Differentiate between various acute kidney injury classification systems and apply to patient case
  • Discuss existing literature and current clinical practice surrounding concomitant VN+PT administration
  • Outline the nephrotoxicity risk and prevalence of VN+PT using new and upcoming data

Speaker(s)/Author(s)

Morgan Bizzell, PharmD
PGY1 Pharmacy Resident

Activity Number

0046-9999-22-199-L01-P
Date: 10/11/22
Time: 01:00 PM - 02:00 PM

CE Hours

1.00

Fee

$10.00
   

   

This session will aim to educate practicing oncology pharmacists on the clinical presentation and management of resectable NSCLC. The presentation will consist of a brief overview of NSCLC, comparison of neoadjuvant and adjuvant management strategies and the recent literature supporting their use, and review patient-specific and logistical factors that may influence when selecting peri-adjuvant systemic therapy.
 
 

Objectives

  • Review current and emerging neoadjuvant and adjuvant systemic therapies
  • Discuss practical considerations and patient specific factors that may impact treatment selection

Speaker(s)/Author(s)

Lindsay Kohler, PharmD
PGY1 Acute Care Pharmacy Resident

Activity Number

0046-9999-22-200-L01-P
Date: 10/11/22
Time: 03:00 PM - 03:30 PM

CE Hours

0.50

Fee

$5.00

Location

Online
   

   

This session will outline updated practices in the management of women with advanced stage ovarian cancer. We will highlight the genetic abberations present in this population, their implication on treatment approaches, and discuss current frontline maintenance strategies and the data to support their use. In the end, the goal will be to define which patients with advanced-stage ovarian cancer should receive maintenace therapy with a PARP inhibitor.
 
Slides have been added to this module. You must first sign into your registered account to access that content.

Objectives

  • Describe the epidemiology, pathophysiology, and types of ovarian cancer
  • Review the treatment paradigm for maintenance therapies in ovarian cancer
  • Review available data for the use of PARPi therapy for maintenance treatment in non-recurrent, BRCAwt/HRp disease

Speaker(s)/Author(s)

Erin Dark, PharmD
PGY1 Ambulatory Care Pharmacy Resident

Activity Number

0046-9999-22-202-L01-P
Date: 10/11/22
Time: 03:30 PM - 04:00 PM

CE Hours

0.50

Fee

$5.00
   

 

   

Allogeneic bone marrow transplant (BMT) is a process by which diseased bone marrow cells are eradicated via high doses of chemotherapy and/or radiation, then subsequently replaced by transplanted donor cells from a donor who is not the recipient. Allogeneic BMT is a curative option in a growing number of diseases- both malignant and non-malignant. However, it is a complex treatment regimen that is expensive and requiring a lot of external support. Inequalities in transplant referral, utilization, and outcomes/survival in patients of non-White backgrounds are well-documented in the literature, specifically patients who are reported to be of Asian, Black, and Hispanic descent. The disparities are due to several factors that can ultimately be separated into two categories: pre-transplant and post-transplant. As pharmacists & key members on the interdisciplinary team, we can play a role in improving referral rates and reducing time to referral to BMT. Additionally, welcoming advances in post-transplant GVHD prophylaxis regimens, such as post-transplant cyclophosphamide, can open up the donor source pool, allowing more patients of diverse backgrounds to be eligible for transplant. These advances have demonstrated improved outcomes in patients who only have a partial HLA-match.
 
 

Objectives

  • Identify racial and ethnic disparities that exist in allogeneic bone marrow transplant.
  • Describe the factors that contribute to differences in transplant referral, utilization, and outcomes.
  • Review current literature on advances in practice and other potential solutions to improve outcomes in non- White patients in which allogeneic BMT is indicated.

Speaker(s)/Author(s)

Callee Brooks, PharmD
PGY1 Pharmacy Resident

Activity Number

0046-9999-22-217-L01-P
Date: 10/19/22
Time: 03:00 PM - 03:30 PM

CE Hours

0.50

Fee

$5.00
   

   

This session will educate pharmacists on current management strategies for patients IDH-1-mutated AML who are not suitable for standard induction strategies. Focus will be placed on the emerging literature regarding the use of either combination azacitide and ivosidenib or azacitidine and venetoclax in this population.

Objectives

  • Discuss the pathophysiology and prognosis of isocitrate dehydrogenase-1 (IDH1)-mutated acute myeloid leukemia
  • Discuss the literature regarding available treatment modalities for IDH1-mutated AML
  • Outline the clinical role of azacitidine/ivosidenib in the treatment of newly diagnosed IDH1-mutated AML

Speaker(s)/Author(s)

Hailey Hirata, PharmD
PGY-1 Pharmacy Resident - Acute Care Track

Activity Number

0046-9999-22-209-L01-P
Date: 10/19/22
Time: 03:30 PM - 04:00 PM

CE Hours

0.50

Fee

$5.00
   

 

   

This presentation will inform the health care provider about gender affirming therapy and how to support the medical needs of transgender youth
 
Join Zoom Meeting
Meeting ID: 965 4271 5944
Passcode: 483935

Objectives

  • Define relevant vocabulary used in gender affirming care
  • Describe health disparities impacting trans* youth
  • Discuss gender affirming therapy options
  • Recognize pharmacists' impact in gender affirming care

Speaker(s)/Author(s)

Joanna Billings, PharmD
PGY1 Pharmacy Resident

Activity Number

0046-9999-22-211-L01-P
Date: 10/20/22
Time: 01:00 PM - 02:00 PM

CE Hours

1.00

Fee

$10.00
   

 

   

This will be a knowledge-based activity to increase pharmacist awareness of emerging evidence-based uses of ketamine within the emergency department and intensive care unit. Active learning will be assessed using multiple choice questions.

Objectives

  • Describe the indications, mechanism of action, pharmacokinetics, and adverse effects of ketamine
  • Summarize pertinent literature that has led to the expanded use of ketamine within the emergent and critical care patient populations
  • Differentiate the place in therapy of ketamine for various indications within the emergency department or ICU
  • Outline pertinent details from a patient case to determine the appropriateness of treatment with ketamine

Speaker(s)/Author(s)

Victoria Miles, PharmD, RPh
PGY1 Pharmacy Resident

Activity Number

0046-9999-22-212-L01-P
Date: 10/21/22
Time: 02:00 PM - 03:00 PM

CE Hours

1.00

Fee

$10.00

Location

Online
   

 

   

This session is intended to provide insight into importance elements pharmacists must consider when treating patients who use cannabis products. It will dive into considerations regarding clinical presentations to be knowledgeable of, drug-drug interactions, and unique complications associated with CBD/THC use.
 
Meeting ID: 941 9379 5014
Passcode: 464340

Speaker(s)/Author(s)

Alissa Clayton , PharmD
PGY1 Pharmacy Resident, Ambulatory Care

Activity Number

0046-9999-22-218-L05-P
Date: 10/25/22
Time: 01:00 PM - 02:00 PM

CE Hours

1.00

Fee

$10.00